Washed microbiota transplantation promotes homing of group 3 innate lymphoid cells to the liver via the CXCL16/CXCR6 axis: a potential treatment for metabolic-associated fatty liver disease-Reference-Cited by-同舟云学术

Washed microbiota transplantation promotes homing of group 3 innate lymphoid cells to the liver via the CXCL16/CXCR6 axis: a potential treatment for metabolic-associated fatty liver disease

Published:2024-06-28 Issue:1 Volume:16 Page:
ISSN:1949-0976
Container-title:Gut Microbes
language:en
Short-container-title:Gut Microbes

Author:

Zhong Hao-Jie¹²³,Zhuang Yu-Pei²⁴,Xie Xinqiang³,Song Jia-Yin²,Wang Si-Qi²,Wu Lei²³,Zhan Yong-Qiang¹,Wu Qingping³,He Xing-Xiang²^ORCID

Affiliation:

1. Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China

2. Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China

3. Guangdong Provincial Key Laboratory of Microbial Safety and Health, State Key Laboratory of Applied Microbiology Southern China, Institute of Microbiology, Guangdong Academy of Sciences, Guangzhou, China

4. Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

Funder

Key-Area Research and Development Program of Guangdong Province

Education Department of Guangdong Province

Shenzhen Science and Technology Program

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/19490976.2024.2372881

Reference60 articles.

1. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD

2. Redefining fatty liver disease: an international patient perspective

3. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group

4. Changing epidemiology, global trends and implications for outcomes of NAFLD

5. NASH drug treatment development: challenges and lessons